Table 2.
Risk of Meningioma in the Cohort in Relation to Sex, Country of Residence, and Initial Diagnosis Leading to GH Treatment
| All Initial Diagnoses | Initial Diagnosis Cancer | Initial Diagnosis Noncancer | ||||
|---|---|---|---|---|---|---|
| n |
SIR (95% CI) | n | SIR (95% CI) | n | SIR (95% CI) | |
| Sex | ||||||
| Male | 18 | 83.7 (52.7, 132.8)a | 18 | 464.9 (292.9, 737.8)a | 0 | 0.0 (0.0, 20.5) |
| Female | 20 | 69.2 (44.7, 107.3)a | 19 | 467.6 (298.3, 733.1)a | 1 | 4.0 (0.6, 28.6) |
| Country of residence | ||||||
| Belgium | 0 | 0.0 (0.0, 92.2) | 0 | 0.0 (0.0, 368.9) | 0 | 0.0 (0.0, 92.2) |
| Netherlands | 9 | 84.4 (43.9, 162.2)a | 9 | 503.4 (261.9, 967.5)a | 0 | 0.0 (0.0, 41.0) |
| Sweden | 7 | 40.5 (19.3, 85.0)a | 7 | 385.6 (183.8, 808.8)a | 0 | 0.0 (0.0, 24.6) |
| Switzerland | 0 | 0.0 (0.0, 368.9) | 0 | 0.0 (0.0, 6148.1) | 0 | 0.0 (0.0, 368.9) |
| United Kingdom | 22 | 126.8 (83.5, 192.6)a | 21 | 593.5 (387.0, 910.3)a | 1 | 7.2 (1.0, 51.4) |
| Diagnosis leading to GH treatment | ||||||
| CNS tumor | 29 | 533.7 (370.9, 768.0)a | 29 | 533.7 (370.9, 768.0)a | — | — |
| Hematological malignancy | 7 | 319.2 (152.2, 669.5)a | 7 | 319.2 (152.2, 669.5)a | — | — |
| Non-CNS solid tumor | 1 | 324.1 (45.6, 2300.6)b | 1 | 324.1 (45.6, 2300.6)b | — | — |
| Turner syndrome | 1 | 9.2 (1.3, 65.0)c | — | — | 1 | 9.2 (1.3, 65.0)c |
| Isolated growth failure | 0 | 0.0 (0.0, 19.4) | — | — | 0 | 0.0 (0.0, 19.4) |
| Other noncancer | 0 | 0.0 (0.0, 30.7) | — | — | 0 | 0.0 (0.0, 30.7) |
| Total | 38 | 75.4 (54.9, 103.6)a | 37 | 466.3 (337.8, 643.5)a | 1 | 2.4 (0.3, 16.7) |
a
P < 0.001.
b
P < 0.01.
c
P < 0.05.